Fumagillin treatment of hepatocellular carcinoma in rats: An in vivo study of antiangiogenesis

Table 3 Inhibitory effect of fumagillin on hepatic tumor growth and metastasis in LEW rats at wk 20 and 24.

Treatment groups	Liver tumor (B/C-A) (g, median)		No. of HCC-involved organs1
	20th wk	24th wk	20th wk	24th wk
Group B DEN only (n = 5)	0.641	0.791	3	3
	[0.58-0.70]	[0.70-0.90]	[2-3]	[3-3]
Group C DEN + Fumagillin (n = 5)	0.37	0.39	1	1
	[0.35-0.42]	[0.35-0.47]	[1-2]	[1-2]
P value	0.009	0.009	0.007	0.004

Weight: median [range] of 5 rats in each step; P value: non-parametric test (Mann-Whitney U test);

¹organs involved: 1 (liver only), or 2 to 3 (lung or/and peritoneum, in addition to liver). Liver tumor (B/C-A): B rat liver tumor weight = liver weight of group B rat minus that of group A rat; C rat liver tumor weight = liver weight of group C rat minus that of group A rat.